Objective To explore the clinical features and survival of patients with advanced gastric cancer or gastroesophageal junctional cancer (GC/GEJC) treated by chemotherapy plus immunotherapy.
Methods From May 2015 to May 2019, patients with advanced GC/GEJC who were treated in the department of oncology, the first medical center of Chinese PLA General Hospital were included in our study, with 37 patients treated with chemotherapy (fluorouracil/capecitabine/tegafur combined with platinum- or taxane-based drugs) as chemotherapy group, and another 34 patients treated with chemotherapy combined with immune checkpoint inhibitors (PD-1, Nivolumab or Pembrolizumab) as combination group. Clinical outcomes were observed and compared between the two groups.
Results The progression-free survival (PFS) was 3.93 months (95% CI: 1.56-6.30) in the combination group and 4.97 months (95% CI: 3.36-6.58) in the chemotherapy group (P=0.242); and the overall survival (OS) was 14.37 months (95% CI: 8.17-20.57) and 12.52 months (95% CI: 9.82-15.22) (P=0.101); ORR was 23.5% and 18.9% (P=0.634), DCR was 79.4% and 75.7% (P=0.707). Mild (GradeⅠ-Ⅱ) adverse reactions were found in the two groups.
Conclusion Chemotherapy combined with immunotherapy has certain clinical benefits for patients with advanced GC / GEJC, and further exploration of treatment strategies and screening of target population for immunotherapy are still needed.
DownLoad: